Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
261.6 INR | -2.08% | -5.98% | +4.81% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.81% | 3.82B | |
-3.19% | 102B | |
+1.81% | 96.07B | |
-1.80% | 21.66B | |
-17.66% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-27.90% | 13.79B | |
-0.46% | 13.33B | |
+20.24% | 10.94B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Biologics Launches Insulin Glargine Injections in US